Last mentioned: Mar 19, 2026
Earnings Call
Management hosts a conference call to discuss 2025 performance and 2026 outlook.
Financial Reporting
XOMA files Q4 and Full Year 2025 financial results with the SEC.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Asset Acquisition
Completion of a significant acquisition of royalty rights from a clinical-stage partner.
Strategic Disclosure
XOMA issues Regulation FD disclosure regarding portfolio updates.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Daybue Approval
FDA approves Daybue as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
This page surfaces every story mentioning Acadia Pharmaceuticals across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Acadia Pharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |